Preclinical and clinical study on \([^{18}\text{F}]\text{DRKXH1}\): a novel \(\beta\)-amyloid PET tracer for Alzheimer’s disease

MiaoMiao Xu\(^1\) · Jun Guo\(^1\) · JiaCheng Gu\(^2\) · LinLin Zhang\(^1\) · ZiHao Liu\(^1\) · Lin Ding\(^1\) · HongLiang Fu\(^1\) · YuFei Ma\(^1\) · Sheng Liang\(^1\) · Hui Wang\(^1\)

Received: 18 January 2021 / Accepted: 19 May 2021 / Published online: 22 July 2021
© The Author(s) 2021

Abstract

Background The deposition of \(\beta\)-amyloid (A\(\beta\)) in the brain is a biomarker of Alzheimer’s disease (AD). Highly sensitive A\(\beta\) positron emission tomography (PET) imaging plays an essential role in diagnosing and evaluating the therapeutic effects of AD.

Aim To synthesize a new A\(\beta\) tracer \([^{18}\text{F}]\text{DRKXH1}\) (5-(4-(6-(2-\([^{18}\text{F}]\)fluoroethoxy)ethoxy)imidazo[1,2-alpha]pyridin-2-yl)phenyl) and evaluate the tracer performance by biodistribution analysis, in vivo small-animal PET-CT dynamic scan, ex vivo and in vitro autoradiography, and PET in human subjects.

Methods \([^{18}\text{F}]\text{DRKXH1}\) was synthesized automatically by the GE FN module. Log \(D\) (pH 7.4) and biodistribution of \([^{18}\text{F}]\text{DRKXH1}\) were investigated. Small-animal-PET was used for \([^{18}\text{F}]\text{DRKXH1}\) and \([^{18}\text{F}]\text{AV45}\) imaging study in AD transgenic mice (APPs\(\text{we/PSEN1dE9}\)) and age-matched normal mice. The distribution volume ratios (DVRs) and standardized uptake value ratios (SUVRs) were calculated with the cerebellum as the reference region. The deposition of A\(\beta\) plaques in the brain of AD transgenic mice was determined by ex vivo autoradiography and immunohistochemistry. In vitro autoradiography was performed in the postmortem brain sections of AD patients and healthy controls. Two healthy control subjects and one AD patient was subjected to in vivo PET study using \([^{18}\text{F}]\text{DRKXH1}\).

Results The yield of \([^{18}\text{F}]\text{DRKXH1}\) was 40%, and the specific activity was 156.64 \(\pm\) 11.55 GBq/\(\mu\)mol. \([^{18}\text{F}]\text{DRKXH1}\) was mainly excreted through the liver and kidney. The small-animal PET study showed high initial brain uptake and rapid washout of \([^{18}\text{F}]\text{DRKXH1}\). The concentration of \([^{18}\text{F}]\text{DRKXH1}\) was detected in the cortex and hippocampus of AD transgenic mouse brain. The cortex DVR of AD transgenic mice was higher than that of WT mice (\(P < 0.0001\)). Moreover, the SUVRs of AD transgenic mice were higher than those of WT mice based on the 0–60-min dynamic scanning. In vitro autoradiography showed a significant concentration of tracer in the A\(\beta\) plaque-rich areas in the brain of AD transgenic mice. The DVR value of \([^{18}\text{F}]\text{DRKXH1}\) is higher than that of \([^{18}\text{F}]\text{AV45}\) (1.29 \(\pm\) 0.05 vs. 1.05 \(\pm\) 0.08; \(t = 5.33, P = 0.0003\)). Autoradiography of postmortem human brain sections showed \([^{18}\text{F}]\text{DRKXH1}\)-labeled A\(\beta\) plaques in the AD brain. The AD patients had high retention in cortical regions, while healthy control subjects had uniformly low radioactivity uptake.

Conclusions \([^{18}\text{F}]\text{DRKXH1}\) is an A\(\beta\) tracer with high sensitivity in preclinical study and has the potential for in vivo detection of the human brain.

Keywords Alzheimer’s disease (AD) · \(\beta\)-Amyloid · Amyloid imaging · Positron emission tomography (PET) · \([^{18}\text{F}]\text{DRKXH1}\)

Introduction

Alzheimer’s disease (AD) is the leading cause of dementia in elderly people worldwide, which emerges as one of the significant challenges to the health care system in the twenty-first century [1].

The typical pathophysiological changes of AD are the deposition of extracellular neuroinflammatory plaques...
and nerve fiber tangles in neurons. The deposition of β-amyloid (Aβ) plaques and phosphorylated tau protein results in neuronal damage and brain function damage. Nevertheless, the only gold standard for the diagnosis of AD is a detailed brain autopsy on the patient’s brain [2]. Nowadays, the main clinical diagnostic methods of AD include cognition and behavioral evaluation. When clinical symptoms, such as cognitive decline, occur, neurons are damaged irreversibly, and the potential repair opportunity is missed [3]. Therefore, sensitive and non-invasive detection of pathophysiological biomarkers is needed to facilitate early diagnosis, which is essential for the intervention treatments and delaying the development of AD. Aβ accumulation is an early event of AD and is widely considered the initial trigger for a cascade of other pathophysiological events [4]. Significantly advancing the diagnosis time of AD, in vivo imaging of Aβ plaques in the brain based on positron emission tomography (PET) plays an essential role in the pathophysiological mechanisms underlying AD development and the efficacy evaluation of the Aβ drug therapy [5].

In the past 20 years, a series of Aβ radioactive tracers, such as benzothiazole derivatives [11C]PIB (2-[4-(methyl-[11]C)-amino) phenyl]-6-hydroxybenzothiazole) [6, 7], [11C]AZD2184 (2-[6-(methylamino) pyridin-3-yl]-1,3-benzothiazol-6-ol), have been developed to visualize the deposition of Aβ plaques in the brain [8]. Although [11C]PIB is the most intensively studied tracer, its short half-life limits the clinical application. 18F-fluorination tracer has a suitable half-life, which enables the applicability of PET in a wide patient population. [18F]Flutemetamol (2-(3-[18F]4-(methylamino) phenyl)-1,3-benzothiazole-6-ol) [9] and [18F]AV45 ((E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)pyridine-3-yl)vinyl)-N-methyl benzamine) [10] have been approved for clinical use. Nevertheless, these agents can detect Aβ plaques in AD patients’ brains; however, the relatively high retention of white matter decreases the signal-background ratio [8]. Moreover, these tracers cannot detect amyloid oligomers, which contain neurotoxic substances and appear earlier than Aβ plaques.

Therefore, it is crucial to develop a new type of Aβ radioactive tracer to resolve these issues. [125I]DRK092 is an imidazopyridine single photoemission computed tomography (SPECT) probe with a high affinity to Aβ. Chen et al. reported that the binding power of [125I]DRK092 to Aβ was significantly higher than that of [125I]IMPy (2-(49-dimethylaminophenyl)-6-iodoimidazo[1,2-a]pyridine) [11, 12], with a high brain uptake rate and low nonspecific binding. Positron emission tomography-computed tomography (PET-CT) is advantageous in diagnosing nervous system diseases because it has a higher resolution than SPECT. However, this restricts the application of [125I] DRK092 in PET-CT [13].

Thus, we modified the structure of DRK092 to improve its pharmacokinetics and facilitate [18F] labeling. In this study, we synthesized the new compound [18F]DRKXH1 and investigated a fully automated synthesis method of [18F] DRKXH1, which would be beneficial for future application. Herein, we evaluated the tracer performance by biodistribution analysis, in vivo small-animal PET-CT dynamic scan, ex vivo and in vitro autoradiography, and PET in human subjects.

**Materials and methods**

**Animals**

C57BL/6 mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. AD transgenic mice (Genotype: APPswe/PSEN1dE9) were used in this study. The present study was approved by the Laboratory Animal Ethics and Welfare Committee Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (approval no. XHEC-F-2019–062). The Experimental Committee on Animal Ethics of Xinhua Hospital guidelines were followed for the care and use of animals. All animal experiments followed the animal welfare committee recommendations.

**Radiosynthesis of [18F]DRKXH1**

The precursors and standard materials were purchased from WuXi AppTec Co. Ltd (Qidong, China). The reagents used in this study were commercial products and did not need further purification. The [18F]-fluoride produced by the accelerator was transferred to the module, dehydrated, and placed in the reaction tube, as described previously [14].

The precursor (3 mg) was dissolved in the dimethylformamide solution and heated at 120 °C for 20 min. Then, 2 mL saline was added to the reaction tube and subjected to high-performance liquid chromatography. The distillate was collected after 13 min and evaporated using a rotary evaporator for 10 min at 180 °C. Next, 5 mL saline was injected into the evaporator. The evaporator’s solution was filtered through a 0.22 μm sterile membrane (Millex-GV, Millipore).

HPLC separation conditions: HPLC Column, XBridge C18, 10 × 250 mm, 10 μm (Waters, Milford, MA); mobile phase: 0.1% TFA + MeCN; flow rate 6 ml/min; conditions: 0–3 min 5%; 3–10 min 5–25%; 10–25 min 25–40%; 25–35 min 40%; 35–40 min 40–90%; 40–45 min 90%. The purified solution was identified by analytical HPLC. HPLC condition: Column, XBridge C18, 4.6 × 250 mm, 10 μm (Waters, Milford, MA), mobile phase: 45%: 55% acetonitrile: water, flow rate: 1 ml/min, UV: 350 nm. The purified solution was mixed with [19F]DRKXH1 standard and injected into HPLC system to identify whether the product in the solution was [18F]
DRKXH1. [18F]-AV45 was radiolabeled according to a previously reported procedure [15].

**Lipophilicity measurement**

According to the liquid–liquid partition method (shaking flask method), Log D7.4 of [18F]DRKXH1 was measured by partition between n-octanol and sodium phosphate buffer (pH 7.4) at room temperature [16].

**Biodistribution**

A total of 30 wild-type (WT) mice (8 weeks old, female, 21–23 g) were used for the biodistribution study. [18F]DRKXH1 was injected into the tail vein. Then, the mice were euthanized by inhaling 100% carbon dioxide at the indicated time points of 1, 5, 15, 30, 45, and 60 min, and the group of each time point consisted of 5 mice. Subsequently, the mice were dissected, and the blood, whole brain, heart, liver, small intestine, spleen, lung, kidney, rectus femoris muscle, and femur were excised for weighed radioactivity count by a gamma counter (SN-695, Solar Ring Photoelectric Instrument, Shanghai, China). The enumeration data were converted into the percentage of the injected dose per gram of wet issue (% ID/g).

**In vivo small-animal-PETCT dynamic scan and MRI**

In this PET-CT study, 22-month-old AD transgenic mice (female, n = 6) and age-matched WT mice (female, n = 5) were enrolled. The PET imaging used small-animal PET-CT (Siemens Medical Solutions, Knoxville, TN, USA). The scanning was started immediately after injection of [18F]DRKXH1 (17.46 ± 0.76 MBq) or [18F]-AV45 (17.53 ± 0.64) into mice with a tail vein indwelling needle. The dynamic scanning lasted for 60 min, and the acquisition was divided into 29 frames (12 × 10 s, 6 × 30 s, and 11 × 300 s). The PET scan data were modeled according to the protocols reported previously [17].

Mice were put in a radiofrequency coil and placed in an 11.7 T Bruker BioSpec high-field MRI system (Bruker BioSpin MRI GmbH, Ettlingen, Germany). Based on the MRI template images, we outlined cortex, cerebellum, whole brain, hippocampus, and petrous bone as the regions of interest (ROIs) to generate time-activity curves (TACs). The cerebellum was selected as the reference region, and the cortex was selected as the Aβ-rich region for analysis. A simplified reference Logan model was used instead of the plasma input function to calculate the distribution volume ratios (DVR) based on the 0–60 min dynamic PET scan [18]. On the other hand, standardized uptake value ratios (SUVRs) were calculated relative to the cerebellum for the entire dynamic PET scan.

The 22-month-old AD transgenic mice (female, n = 3) were assessed by dynamic PET scan for displacement studies. For this, [19F]DRKXH1 (10 mg/kg) was injected 40 min after [18F]DRKXH1 (18.15 ± 1.33 MBq) injection [19], and the whole brain was drawn as ROI to obtain the TAC during the 0–60 min dynamic.

**Ex vivo autoradiography**

The 22-month-old AD transgenic mice (female, n = 6) and age-matched WT mice (female, n = 6) were injected with [18F]DRKXH1 (18.94 ± 0.88 MBq) into the tail vein. The animals were euthanized at 30, 40, and 60 min; then, the brain was removed immediately and sliced into 100-μm-thick sections. These sections were placed on an imaging plate (BAS-MS 2025, FUJIFILM, Japan) and exposed for 4 h, followed by scanning with Amersham™ Typhoon™ Biomolecular Imager (GE Healthcare) and the autoradiograms were analyzed by using ImageQuant TL 8.1 software (GE Healthcare). The cortex and cerebellum were drawn as ROIs.

**In vitro autoradiography**

The paraffin brain Sects. (30 μm) of AD patients, healthy control subjects, and 22-month-old AD transgenic mice were incubated with [18F]DRKXH1 (0.3 nM) in 50 mM Tris–HCl buffer containing 40% ethanol for 1 h at room temperature [10]. [19F]DRKXH1 (10 μM) was incubated with [18F]DRKXH1 for the inhibition experiments [20]. Then, the sections were washed with saturated Li₂CO₃ in 40% ethanol, dipped into 40% ethanol for 2 min, and rinsed under flowing water for 30 s [10]. After drying, the brain sections were placed on an imaging plate (BAS-MS 2025, FUJIFILM, Japan) and exposed for 4 h, followed by scanning with Amersham™ Typhoon™ Biomolecular Imager (GE Healthcare).

**Immunohistochemical staining**

The immunostaining was performed using Aβ1-42 (1:250 dilution) antibody (the detailed protocols are provided in the supplementary information). The human brain sections were stained for thioflavin-S, according to the methods described previously [21].

**PET study in human subjects**

Based on the preclinical findings, we enrolled AD patients and healthy control subjects in performing a PET study after the injection of [18F]DRKXH1. The present study aimed to evaluate the effectiveness of [18F]DRKXH1 in distinguishing AD patients from healthy individuals. This study complied

 Springer
with the Declaration of Helsinki and was approved by the Ethics Committee Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (approval no. XHEC-F-2019–120). All subjects signed informed consent before participation in the study.

The AD patients were recruited, examined, and diagnosed by qualified attending neurologists. All physicians abided by the uniform diagnostic criteria, including detailed medical history and mini-mental state examination (MMSE).

All subjects underwent a PET assessment at 45 min after intravenous bolus injection of $^{[18F]}$DRKXH1 (370 MBq). Siemens Biograph 64PET/CT (Erlangen, Germany) was used for three-dimensional (3D) scanning. Before PET scanning, a low dose CT transmission scan was performed, and attenuation correction was performed. The image reconstruction was carried out by ordered subset expectation maximization 3D (OSEM 3D) method.

Statistical analyses

All statistical analyses were performed using an IBM Statistical Package for Social Sciences. (SPSS) 22.0. All quantitative data were presented as mean ± standard deviation (SD) and compared using a two-sample Student’s $t$ test. Statistical significance was set at $P < 0.05$.

Results

Radiosynthesis of $^{[18F]}$DRKXH1

The multifunctional module automated synthesis of $^{[18F]}$DRKXH1 required approximately 60 min, with a yield after decay correction of 40% and specific activity of 156.64 ± 11.55 GBq/μmol. The reaction equation is shown in Fig. 1. $^{[18F]}$AV45 automated synthesis required approximately 50 min, with a yield after decay correction of 43% and specific activity of 176.43 ± 6.75 GBq/μmol.

Lipophilicity measurement

The lipid-water distribution coefficient evaluated the lipophilicity of the probe and predicted the ability of the tracer to pass through the blood–brain barrier. Typically, the optimum log $D$ (pH 7.4) range of Aβ tracer is about 1.5–3.5 [12], and that of $^{[18F]}$DRKXH1 measured by the liquid–liquid partition method (shaking flask method) was 2.78 ± 0.09 ($n = 5$).

Biodistribution

The biodistribution results revealed that the liver, kidney, and lung had a high uptake of $^{[18F]}$DRKXH1 in the initial stage. The radioactivity in the lung, heart, and blood was rapidly cleared, while that in the liver and kidney was clarified slowly. The radioactivity in the small intestine increased gradually, which was similar to the previously reported distribution of Aβ imaging agents [22]. After injecting $^{[18F]}$DRKXH1, the radioactivity of the femur was initially low, increased slightly at 5 min, and then remained stable (Fig. 2).

In vivo small-animal-PETCT dynamic scan and MRI

In this study, the bodyweight of AD transgenic mice was significantly higher than that of WT mice (46.63 ± 1.71 g vs. 23.04 ± 1.13 g, $t = 25.606$, $P < 0.001$). In the imaging of 5–60-min frame fusion, we noticed a distinct radioactivity concentration in the cortex and other brain regions of AD transgenic mice. However, no specific radioactivity concentration was observed in the whole brain region of WT mice (Fig. 3A and B). The TACs of 0–60 min showed that the radioactivity uptake in the brain of AD transgenic and WT mice reached a peak at 2 min after injection of $^{[18F]}$DRKXH1 and eluted rapidly (Fig. 3C). However, the tracer in the brain of AD transgenic mice was eluted more slowly than that of WT mice (Fig. 3C-E). Then, we fused the PET images with MR images and found that the radioactive concentration foci in the brain of AD transgenic mice were located in the cortex and hippocampus (Fig. 3A and B).

Next, we drew the cortex, hippocampus, and the cerebellum of AD transgenic mice as ROIs. Considering the cerebellum as the reference area, we obtained the SUVR of the cortex to the cerebellum and hippocampus to the cerebellum (Fig. 3F). The DVR value of AD transgenic mice was significantly higher than that of WT mice (1.29 ± 0.05 vs. 0.95 ± 0.04; $t = 10.35$, $P < 0.0001$) (Fig. 3G).

To further evaluate the ability of $^{[18F]}$DRKXH1 to detect Aβ plaques in the brain of AD transgenic mice, we directly compared the dynamic PETCT imaging results of $^{[18F]}$DRKXH1 and $^{[18F]}$AV45 in AD transgenic mice (Fig. 4A). The retention of $^{[18F]}$DRKXH1 in the cerebellum is less than that of $^{[18F]}$AV45 (Supplements Fig. 1). The clearance
rates of the two tracers in the brain of AD transgenic mice were similar (Supplements Fig. 1). The DVR value of $[^{18}\text{F}]$ DRKXH1 was higher than that of $[^{18}\text{F}]$-AV45 (1.29 ± 0.05 vs. 1.05 ± 0.08; $t$ = 5.33, $P$ = 0.0003) (Fig. 4B).

In the 60-min dynamic scan, the TAC of petrous bone showed that radioactivity increased at the initial stage (0–5 min) but remained stable subsequently (Fig. 3H).

Next, we conducted displacement experiments to evaluate the specificity of $[^{18}\text{F}]$ DRKXH1 binding to Aβ plaques in the brain of AD transgenic mice. Imaging results showed that at 40–60 min, the TAC curves of mouse whole brains were decreased but not significantly (Fig. 3I, J).

Ex vivo autoradiography

We used ex vivo autoradiography to verify that $[^{18}\text{F}]$ DRKXH1 binds to Aβ plaques in the brain of AD transgenic mice. After 30 and 40 min of the imaging agent injection, significant radioactivity concentration was detected in the cortex of AD transgenic mice, but no specific radioactivity concentration was observed in the whole brain region of WT mice (Fig. 5A and B). Radioligand binding was quantified as ratios of radioactivity intensity of cortex to cerebellum (Fig. 5C).

In vitro autoradiography

The brain sections of AD transgenic mice showed dense labeling of the plaques in the cortex and hippocampus regions (Fig. 5C). The autoradiography showed distinct deposition of $[^{18}\text{F}]$ DRKXH1 in the human cortex which enriched Aβ plaques, and there was no specific concentration in a healthy human brain (Fig. 6B). After co-incubation with $[^{19}\text{F}]$ DRKXH1, the radioactivity of the brain sections of mice and human showed a dramatic decrease (Fig. 5E and Fig. 6C).

IHC and thiosemicarbazone S staining

The positive result of diaminobenzidine staining was brown granules. Aβ1-42 IHC showed that the AD transgenic mice cortex and hippocampus had abundant Aβ plaques, while no plaque deposition was observed in the cerebellum (Fig. 5D). Thiosemicarbazone S staining results showed Aβ deposition in human brain (supplement).

PET study in human subjects

In this study, we enrolled 1 AD patient (male, 82 years, MMSE: 17) and 2 healthy control subjects (male, 42 and 50 years old, respectively). In AD patients, we observed significant $[^{18}\text{F}]$ DRKXH1 retention in recognized amyloid deposit areas, such as the parietal and frontal cortex. However, this phenomenon was not observed in healthy control subjects. In both groups, we observed low retention of subcortical white matter and high uptake in the cerebellar cortex, pons, and thalamus (Fig. 7 and Supplement Table 1).

Discussion

The radiochemical labeling of $[^{18}\text{F}]$ DRKXH1 adopts a nucleophilic $[^{18}\text{F}]$ substitution reaction, which is synthesized by a one-step method. The labeling process is simple, the
Fig. 3 In vivo 0-60 min PET imaging with [18F]DRKXH1. A 22-month-old AD transgenic mice; B 22-month-old WT mice. C Whole brain 0-60 min time-activity curves (TACs) of the 22-month-old AD transgenic mice (n=6) and age-matched WT mice (n=5). The AD transgenic mice was outlined by the blue and WT mice was red line in the figure. D Cortex (blue), hippocampus (red), and cerebellum (green) time-activity curves (TACs) of the 22-month-old AD transgenic mice (n=6) and E age-matched WT mice (n=5).

G [18F]DRKXH1 DVR (cortex/cerebellum) group comparisons for 22-month-old AD transgenic mice (n=6) and age-matched WT mice (n=5).

F [18F]DRKXH1 cortex-to-cerebellum SUVRs of 22-month-old AD transgenic mice and age-matched WT mice in 0-60 min dynamic scan. H Petrous bone 0-60 min time-activity curves (TACs) of the 22-month-old AD transgenic mice (n=6).

I, J Displacement study of [18F]DRKXH1 in AD transgenic mice. 0-60-min time-activity curves of whole brain, cortex, hippocampus, and cerebellum. Injected [18F]DRKXH1 at the 40th minute.
automatic synthesis procedure is mature, and the specific activity of [18F]DRKXH1 is high, which meets the criteria of neuroimaging agents for clinical applications.

In PET imaging study, [18F]DRKXH1 is a small molecule and moderate lipophilic tracer. [18F]DRKXH1 shows potential for ideal Aβ PET tracer, indicating that it can penetrate the complete blood–brain barrier and has high initial uptake in the frontal brain of mice [12]. In AD transgenic mice, the brain uptake peaked at 6%ID/g. We observed that the initial brain uptake in AD transgenic mice was higher than that in WT mice. In addition, the bodyweight of AD transgenic mice was significantly higher than that of WT mice (46.63 ± 1.71 g vs. 23.04 ± 1.13 g, \( t = 25.606, P < 0.001 \)), which is consistent with previous reports, wherein high initial brain uptake was detected in high-weight mice [23]. Studies have showed that AD is related to BBB damage, which may lead to increased permeability [24–26]. Therefore, we speculate that this phenomenon may be explained by BBB damage. Moreover, the presence of Aβ in AD transgenic mice, serving as the target site on [18F]DRKXH1, may also cause the higher initial brain uptake in AD transgenic mice. Also, after the injection of [18F]DRKXH1, AD transgenic mice had significantly higher DVR values than WT mice, indicating that [18F]DRKXH1 has a high retention rate in the Aβ-rich brain regions and can locate Aβ plaques in the brain. The shallow non-specific binding provides high signal-to-noise images beneficial to the diagnosis of AD and efficacy evaluation of therapies targeting Aβ. Intriguingly, rodents are susceptible to the defluorination of many [18F] labeled radioactive tracers, leading to a gradual increase in radioactivity in the skeleton [22, 27]. The radioactive spillover from the skull introduced considerable error into the brain regions, as quantified by PET scans [28]. Also, we observed a mild increase in bone radioactivity 0–5 min after injection, which was subsequently stable without apparent detachment during 5–60 min (0.97–1.1% ID/g). [18F]-AV45 is an Aβ imaging agent approved by the FDA. Similar to [18F]-AV45, [18F]-DRKXH1 exhibits uptake that closely mirrored Aβ deposition in the brain, with higher
DVR values than $[^{18}\text{F}]$-AV45. However, the difference in the autoradiography of human brain sections proposed that $[^{18}\text{F}]$DRKXH1 can distinguish between AD patients and healthy controls. Thus, this study verified the binding ability of $[^{18}\text{F}]$DRKXH1 to Aβ, but the experimental verification of the binding power of toxic amyloid oligomers is yet lacking. Next, we plan to perform PET imaging on transgenic mice for longitudinal studies using brain homogenates from these mice of different ages, Aβ fibers in human brain homogenates, and synthetic human Aβ fibers. The binding affinity assay verified the binding ability of DRKXH1 to Aβ oligomers. The results of preclinical

---

**Fig. 3** (continued)

**Fig. 4** A In vivo 0–60 min PET imaging with $[^{18}\text{F}]$DRKXH1 and $[^{18}\text{F}]$AV45 in 22-month-old AD transgenic mice. B DVR (cortex/cerebellum) group comparisons for $[^{18}\text{F}]$DRKXH1 and $[^{18}\text{F}]$AV45 mice ($n=5$). ***$P<0.0005$ (2-sample $t$ test, $1.29\pm0.05$ vs. $1.05\pm0.08$; $t=5.33$, $P=0.0003$)
Fig. 5 Ex vivo autoradiography. A AD transgenic mice; B WT mice; C radioligand binding was quantified as ratios of radioactivity intensity of cortex to cerebellum. D In vitro autoradiography of AD transgenic mice and immunohistochemical staining of Aβ plaques of AD transgenic mice; E in vitro autoradiography using \(^{18}\text{F}\)DRKXH1 + 10 μM \(^{19}\text{F}\)DRKXH1 of AD transgenic mice.
experiments showed that $[^{18}\text{F}]$DRKXH1 has a high binding affinity and excellent imaging potential for Aβ in the brain of AD transgenic mice, low non-specific binding, and is rapidly eluted from the healthy brain.

The initial clinical study results showed noticeable retention of $[^{18}\text{F}]$DRKXH1 in the cortex of AD patients, which did not appear in healthy subjects, indicating the efficiency of the compound in distinguishing between AD patients and healthy individuals. Low subcortical white matter retention was observed in both groups of individuals; however, no significant boundary existed between cortex and white matter in patients with obvious brain atrophy. Considering the false-positive results caused by high non-specific uptake of white matter, low uptake of white matter might contribute to the accuracy and micro detection capability of Aβ deposition. Conversely, the cerebellar cortex, pons, and thalamus also showed high non-specific uptake of $[^{18}\text{F}]$DRKXH1 in AD patients and healthy individuals. Low subcortical white matter retention was observed in both groups of individuals; however, no significant boundary existed between cortex and white matter in patients with obvious brain atrophy. Considering the false-positive results caused by high non-specific uptake of white matter, low uptake of white matter might contribute to the accuracy and micro detection capability of Aβ deposition. Conversely, the cerebellar cortex, pons, and thalamus also showed high non-specific uptake of $[^{18}\text{F}]$DRKXH1 in

Fig. 6  In vitro autoradiography of human brain sections labeled with $[^{18}\text{F}]$DRKXH1. A Healthy control subjects. B AD patient. C In vitro autoradiography using $[^{18}\text{F}]$DRKXH1 + 10 μM $[^{18}\text{F}]$DRKXH1 of AD patient

Fig. 7 $[^{18}\text{F}]$-DRKXH1 PET images of an AD patient and a healthy control subject
both groups. The lack of mechanism explanation and non-specific uptake of the cerebellar cortex might pose challenges to the quantitative analysis of the imaging results. Taken together, the current evaluation results constitute the preliminary imaging report of [18F]DRKXH1, necessitating additional subjects for the kinetic study. The follow-up data might contribute to the further characteristic analysis of [18F]DRKXH1 and the suitable selection of reference region for quantitative analysis.

Collectively, [18F]DRKXH1 is an Aβ tracer with high sensitivity in preclinical study, and has the potential for in vivo detection of the human brain.

Conclusion

In this study, we synthesized a new Aβ tracer [18F]DRKXH1. It showed a high binding affinity at in vivo and in vitro level in the preclinical study. The PET study in human subjects indicated its potential in clinical diagnosis but further research is still needed.

Limitations

This study has some limitations. This study did not use the classical PET tracer such as [11C]PIB and [18F]florbetapir for imaging comparison. We did not use [18F]DRKXH1 to longitudinally monitor Aβ plaques deposition in the brain of transgenic mice.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00259-021-05421-0.

Acknowledgements We thank Chinese Brain Bank Center for kindly providing human tissue. We express our appreciation for providing experimental instruments of Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine.

Funding This research was supported by the National Natural Science Foundation of China (11775143 and 51703126). No other potential conflict of interest relevant to this article was reported.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salo S, et al. Alzheimer’s disease. Lancet. 2016;388:505–17. https://doi.org/10.1016/s0140-6736(15)00124-1.

2. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12:459-509. https://doi.org/10.1016/j.jalz.2016.03.001.

3. Long JM, Holtzman DM. Alzheimer disease: an update on pathology and treatment strategies. Cell. 2019;179:312–39. https://doi.org/10.1016/j.cell.2019.09.001.

4. Mangialasche F, Solomon A, Winblad B, Mecacci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9:702–16. https://doi.org/10.1016/s1474-4422(10)70119-8.

5. Villemagne VL, Duré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225–36. https://doi.org/10.1038/nrneurol.2018.9.

6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19. https://doi.org/10.1002/ana.20009.

7. Bacsak BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:12462–7. https://doi.org/10.1073/pnas.2034101100.

8. Johnson AE, Jeppsson F, Sandell J, Wensbo D, Neelissen JA, Juréus A, et al. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem. 2009;108:1177–86. https://doi.org/10.1111/j.1471-4159.2008.05861.x.

9. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9. https://doi.org/10.2967/jnumed.109.063305.

10. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plagues in the brain. J Nucl Med. 2009;50:1887–94. https://doi.org/10.2967/jnumed.109.065284.

11. Newberg AB, Winttering NA, Plößl K, Hochhold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer’s disease. J Nucl Med. 2006;47:748–54.

12. Cai L, Innis RB, Pike VW. Radioligand development for PET imaging of beta-amyloid (Abeta)–current status. Curr Med Chem. 2007;14:19–52. https://doi.org/10.2174/09298670779793471.

13. Chen CJ, Bando K, Ashino H, Taguchi K, Shiraishi H, Shima K, et al. Biological evaluation of the radioiodinated imidazo[1,2-a]pyrididine derivative DRK092 for amyloid-beta imaging in mouse model of Alzheimer’s disease. Neurosci Lett. 2014;581:103–8. https://doi.org/10.1016/j.neulet.2014.08.036.

14. Ma Y, Guo J, Liang S, Wang H. Improved automated synthesis of (2-((2–6-[18F]fluoro-5-(methylamino) pyridin-2-yl)benzothiazol-6-yl)thio)ethanol ([18F]FINH-Me) via direct radio-fluorination and quality control for Aβ-amyloid imaging. J Nucl Med Mol Imaging. 2019. https://doi.org/10.23736/s1824-7855.19.03163-7.

15. Liu Y, Zhu L, Plößl K, Choi SR, Qiao H, Sun X, et al. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer’s disease. Nucl Med Biol. 2010;37:917–25. https://doi.org/10.1016/j.nucmedbio.2010.05.001.

16. Wang L, Cheng K, Fujinaga M, Yang J, Zhang Y, Hatori A, et al. A facile radiolabeling of [18F]FDPA via spirocyclic iodonium ylides: preliminary PET imaging studies in preclinical models of
neuroinflammation. J Med Chem. 2017;60:5222–7. https://doi.org/10.1021/acs.jmedchem.7b00432.

17. Tang D, Li J, Nickels ML, Huang G, Cohen AS, Manning HC. Preclinical evaluation of a novel TSPO PET ligand 2-(7-butyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N, N-diethylacetamide ((18)F-VU1018A) to image glioma. Mol Imaging Biol. 2019;21:113–21. https://doi.org/10.1007/s11307-018-1198-7.

18. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–40. https://doi.org/10.1097/00004679-199609000-00008.

19. Declercq L, Rombouts F, Koole M, Fierekens K, Mariën J, Langlois X, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58:975–81. https://doi.org/10.2967/jnumed.116.185199.

20. Chen CJ, Bando K, Ashino H, Taguchi K, Shiraishi H, Shima K, et al. In vivo SPECT imaging of amyloid-β deposition with radiiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer’s disease. J Nucl Med. 2015;56:120–6. https://doi.org/10.2967/jnumed.114.146944.

21. Guillotet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol. 1997;42:909–18. https://doi.org/10.1002/ana.410420613.

22. Snellman A, López-Picón FR, Rokka J, Salomaa M, Forloni G, Scheinin M, et al. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APP-swe-Ps1dE9 mouse models of Alzheimer disease. J Nucl Med. 2013;54:1434–41. https://doi.org/10.2967/jnumed.112.110163.

23. Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2005;32:593–600. https://doi.org/10.1007/s00259-005-1780-5.

24. Yamazaki Y, Kanieki Y. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. Int J Mol Sci. 2017;18. https://doi.org/10.3390/ijms18091965.

25. van de Haar HJ, Jansen JFA, van Osch MJP, van Buchem MA, Muller M, Wong SM, et al. Neurovascular unit impairment in early Alzheimer’s disease measured with magnetic resonance imaging. Neurobiol Aging. 2016;45:190–6. https://doi.org/10.1016/j.neurobiolaging.2016.06.006.

26. Festoff BW, Sajja RK, van Dreden P, Cucullo L. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflammation. 2016;13:194. https://doi.org/10.1186/s12974-016-0670-z.

27. Rominger A, Brendel M, Burgold S, Keppeler K, Baumann K, Xiong G, et al. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54:1127–34. https://doi.org/10.2967/jnumed.112.114660.

28. Rominger A, Wagner E, Mille E, Böning G, Esmaeilzadeh M, Wängler B, et al. Endogenous competition against binding of [18F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. Synapse. 2010;64:313–22. https://doi.org/10.1002/syn.20730.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

MiaoMiao Xu1 · Jun Guo1 · JiaCheng Gu2 · LinLin Zhang1 · ZiHao Liu1 · Lin Ding1 · HongLiang Fu1 · YuFei Ma1 · Sheng Liang1 · Hui Wang1

1 Department of Nuclear Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1665, Kongjiang Street, Yangpu District, Shanghai 200092, China
2 Brain Injury Center, Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Head Trauma, Shanghai 200127, China